STOCK TITAN
  1. Home
  2. News
  3. BNGO

Bionano Genomics, Inc. - BNGO STOCK NEWS

Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.

Bionano Genomics, Inc. (Nasdaq: BNGO) is a pioneering company in the life sciences instrumentation sector, dedicated to advancing genome biology understanding through innovative solutions. The company is renowned for its development and marketing of the Saphyr™ system, an ultra-sensitive platform designed for structural variation detection. This system enables researchers and clinicians to accelerate diagnostics and therapeutic target discovery, streamlining studies on chromosomal changes.

Bionano's core mission is to transform genomic analysis through optical genome mapping (OGM) solutions, diagnostic services, and software. Their flagship product, Saphyr™, offers unmatched capabilities in structural variation discovery and the ability to construct comprehensive genome assemblies. This technology is crucial for applications in cancer research, human disease studies, agricultural bioengineering, and genome discovery.

Recent achievements include the detection of unique structural variations and gene fusions in blood cancer samples, underscoring OGM's potential as a complement to traditional sequencing methods. Bionano's OGM technology has shown superior sensitivity and resolution in various studies, highlighting its utility in pediatric leukemia and other cancers.

The company operates globally with significant revenue from the Americas, and it generates product revenue from the sales of OGM and Ionic Purification systems and consumables. Bionano also offers diagnostic testing for neurodevelopmental disabilities through its Lineagen, Inc. d/b/a Bionano Laboratories business and industry-leading genome analysis software that integrates next-generation sequencing and microarray data.

Partnerships with AI-driven companies like Diagens further enhance Bionano's offerings, aiming to improve reproductive health and other clinical applications. Additionally, Bionano continuously upgrades its VIA software and Bionano Solve pipeline to provide researchers with precise and sensitive genomic research tools.

For more information, visit Bionano Genomics and its associated websites, www.bionanolaboratories.com and www.purigenbio.com.

News

Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual Meeting

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the American Society of Hematology (ASH) Annual Meeting and Exposition 2023 will feature a broad range of content covering optical genome mapping's (OGM) utility for research in myeloid cancer, hematological malignancy, leukemia, and blood disorders. Dr. Enze Liu will present findings from a study on the use of OGM to detect structural variants in multiple myeloma. The ASH conference will be held December 9-12, 2023, in San Diego, California and online.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
none
-
News

Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD

Rhea-AI Summary
Bionano Laboratories (BNGO) announced the largest peer-reviewed study on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD). The study showed that the OGM-based laboratory developed test (LDT) was 100% accurate and precise when compared to the prior standard, Southern blot analysis. OGM identified 56% of FSHD1 cases and detected mosaic alleles in 3% of samples. The overall diagnostic yield of OGM and NGS combined was 58%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
-
News

Bionano Announces Publication Demonstrating Utility of OGM to Assess Genome Integrity of CRISPR-Edited Cells as Part of Gene Therapy Development

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a study demonstrating the use of optical genome mapping (OGM) to identify structural variations introduced by CRISPR-Cas9 gene editing of CD4+ T-cells, revealing the potential limitations of such edited cells for therapeutic use. The study found that while ddPCR assays are suitable to characterize certain expected mutations, they may miss large SVs. OGM outperformed karyotyping's resolution and sensitivity, revealing unexpected gene editing events and off-target structural variations. The study highlights the importance of comprehensive genome analysis in developing gene therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
none
News

Bionano Announces Presentation of OGM Utility Across Key Research Applications at the Association for Molecular Pathology Annual Meeting

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced its participation in the Association for Molecular Pathology (AMP) 2023 Annual Meeting and Expo. The company will present a broad range of content covering the utility of optical genome mapping (OGM) for cell and gene therapy and cancer research, including scientific workshops and poster presentations. The sessions will feature leading medical professionals presenting data on the role of structural variants in central nervous system (CNS) tumor analysis and hematological malignancy research conducted using OGM. The company will also showcase innovation in OGM workflow and product developments. In addition, 19 scientific posters will illustrate the application of OGM in research areas including hematological malignancies, solid tumor, constitutional disorders, and cell and gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
none
-
News

Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) reported Q3 2023 revenue of $9.3 million, a 29% increase over Q3 2022. They also announced the installation of 301 Saphyr® systems and the sale of 6,176 nanochannel array flowcells. Additionally, they completed an $80.0 million registered offering and private placement of senior secured convertible notes due 2025 and warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
earnings
-
News

Thompson and Thompson Genetics and Genomics in Medicine Includes OGM in Latest Edition, Notes Workflow’s Performance and Ability to Detect More SVs than LRS at Lower Cost

Rhea-AI Summary
Bionano Genomics announced that optical genome mapping (OGM) was included in the latest edition of Thompson and Thompson Genetics and Genomics in Medicine. OGM is described as a powerful tool for genome analysis, capable of detecting and validating structural variants (SVs) that sequencing techniques may miss. The authors of the book also note that OGM can be less expensive and more precise than long-read sequencing (LRS) in resolving complex SVs. This inclusion is a significant milestone for OGM and highlights its potential in clinical research investigations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.03%
Tags
none
News

Bionano to Present at the 2023 Stifel Healthcare Conference

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its CEO, Erik Holmlin, will present at the 2023 Stifel Healthcare Conference on November 15. The presentation will be available through a webcast and a recording will be accessible on the company's website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.03%
Tags
conferences
-
News

Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) will host a conference call and webcast on November 8, 2023, at 4:30 p.m. ET to report financial results for Q3 2023 and highlight recent corporate progress. Participants can access the live webcast on the Investors page of the Bionano website. A replay will be available on the company's investor relations website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
conferences earnings
-
News

Bionano Announces Presentation of OGM Utility Across Key Applications at the American Society of Human Genetics (ASHG) Annual Meeting

Rhea-AI Summary
Bionano Genomics will participate in the ASHG Annual Meeting 2023, presenting on the utility of optical genome mapping (OGM) in genetic disorder research. The conference will feature scientific presentations, poster sessions, and a sponsored session highlighting the latest research findings using OGM. Bionano's CEO, Erik Holmlin, expressed excitement about the variety and scale of the studies being presented, emphasizing the impact of OGM on genetic research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
News

Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan

Rhea-AI Summary
Bionano Genomics announces financing of $80 million, preliminary Q3 revenue of $9.1-9.3 million, and growth in installed base of Saphyr systems and nanochannel array flowcells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.85%
Tags
earnings

FAQ

What is the current stock price of Bionano Genomics (BNGO)?

The current stock price of Bionano Genomics (BNGO) is $0.2273 as of January 9, 2025.

What is the market cap of Bionano Genomics (BNGO)?

The market cap of Bionano Genomics (BNGO) is approximately 31.8M.

What does Bionano Genomics, Inc. specialize in?

Bionano Genomics specializes in genome analysis solutions, particularly through their Saphyr™ system for structural variation detection.

What is the Saphyr™ system?

The Saphyr™ system is Bionano's high-speed, high-throughput whole genome mapping solution that offers unmatched structural variation discovery capabilities.

What are the applications of Bionano's OGM technology?

Bionano's OGM technology is used in cancer research, human disease studies, agricultural bioengineering, and genome discovery.

What recent achievements has Bionano reported?

Bionano recently reported detecting unique structural variations and gene fusions in blood cancer samples, showcasing OGM's potential as a complement to traditional sequencing methods.

Where does Bionano operate?

Bionano operates globally with significant revenue generated from the Americas, EMEA, and Asia Pacific regions.

What additional services does Bionano offer?

Bionano offers diagnostic testing for neurodevelopmental disabilities and industry-leading genome analysis software that integrates next-generation sequencing and microarray data.

Who are Bionano's key partners?

Bionano partners with companies like Diagens to enhance clinical applications, particularly in reproductive health.

What is the purpose of Bionano's VIA software?

Bionano's VIA software provides researchers with precise and sensitive tools for genomic research, improving visualization, interpretation, and reporting of results.

Are Bionano's products for research or clinical use?

Most of Bionano’s OGM products are for research use only and not for use in diagnostic procedures.

How can I learn more about Bionano Genomics?

You can visit Bionano's main website at www.bionano.com or its associated websites, www.bionanolaboratories.com and www.purigenbio.com, for more information.
Stock BNGO logo
Bionano Genomics, Inc.

Nasdaq:BNGO

BNGO Rankings

#5145 Ranked by Market Cap
N/A Ranked by Dividends

BNGO Stock Data

31.78M
139.65M
0.15%
12.81%
10.25%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO